Idiopathic pulmonary fibrosis (IPF) is a progressive devastating lung disease with substantial
morbidity. It is associated with cough, dyspnea and impaired quality of life. If left untreated …

Introduction Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic
interstitial pneumonias. It is a serious and progressive lung disease with a median survival …

Idiopathic pulmonary fibrosis (IPF) is a severe and often fatal disease with a median survival
of 2–4 years after diagnosis. Since the publication of the German IPF guideline in 2013 new …

At present, the etiology of idiopathic pulmonary fibrosis (IPF) remains elusive. Over the past
two decades, however, researchers have identified and described the underlying processes …

Abstract Background The INSIGHTS-IPF registry provides one of the largest data sets of
clinical data and self-reported patient related outcomes including health related quality of life …

Idiopathic pulmonary fibrosis (IPF) is associated with a fatal prognosis and manifests in
patients over 60 years old who may have comorbidities. The prevalence and impact of …

Idiopathic pulmonary fibrosis (IPF) is a chronic, debilitating, fibrotic lung disease leading to
respiratory failure and ultimately to death. Being the prototype of interstitial lung diseases …

Background Pirfenidone is an oral antifibrotic agent that has been shown to reduce the
decline in lung function in patients with idiopathic pulmonary fibrosis (IPF). We performed an …

Medical therapy for idiopathic fibrosis remains controversial. Idiopathic pulmonary fibrosis
(IPF) was uniformly a disease that progressed inexorably, typically leading to death within 3 …

Background: Comorbidities in idiopathic pulmonary fibrosis (IPF) affect quality of life,
symptoms, disease progression and survival. It is unknown what are the comorbidities in …